Vaccine independence, local competences and globalisation: Lessons from the history of pertussis vaccines

Social Science and Medicine

Volumn 63, Issue 7, 2006, Pages 1825-1835

  Blume, Stuart ^a   Zanders, Mariska ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b NETHERLANDS VACCINE INSTITUTE   (Netherlands)

Author keywords

Globalisation; Netherlands; Pertussis; Vaccine choice; Vaccine history; Vaccine system

Indexed keywords

ACELLULAR VACCINE; INACTIVATED VACCINE; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE;

GLOBALIZATION; PRIMARY HEALTH CARE; VACCINATION; VACCINE;

ARTICLE; COMPETENCE; DRUG CHOICE; HEALTH PROGRAM; HUMAN; IMMUNIZATION; NETHERLANDS; PERTUSSIS; POLITICS; PRESCRIPTION; VACCINATION;

DECISION MAKING; HUMANS; NETHERLANDS; PERTUSSIS VACCINE; POLITICS; VACCINES, ACELLULAR; WHOOPING COUGH;

BENELUX; EURASIA; EUROPE; NETHERLANDS; WESTERN EUROPE;

EID: 33746811482     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.socscimed.2006.04.014     Document Type: Article

References (43)

1. Bayer R., and Colgrove J. Rights and dangers: Bioterrorism and the ideologies of public health. In: Moreno J.D. (Ed). In the wake of terror: Medicine and morality in a time of crisis (2003), MIT Press, Cambridge, MA 51-74
2. Bentsi-Enchill A.D., Halperin S.A., Scott J., MacIsaac K., and Duclos P. Estimates of the effectiveness of a whole-cell pertussis vaccine from an outbreak in an immunized population. Vaccine 15 (1997) 301-306
3. Berger S. Globalisation and politics. Annual Reviews of Political Science 3 (2000) 43-62
4. Blume S. Lock in, the state and vaccine development: Lessons from the history of the polio vaccines. Research Policy 34 (2005) 159-173
5. Blume S., and Geesink I. A brief history of polio vaccines. Science 288 (2000) 1593-1594
6. Blume S., and Geesink I. Vaccinology: An industrial science?. Science and Culture 9 (2000) 41-72
7. Brugha R., Starling M., and Walt G. GAVI, the first steps: Lessons for the global fund. Lancet 359 (2002) 435-438
8. Cohen H. De immunologische basis van de toepassing van DKTP vaccin. Verhandelingen van de Koninklijke Academie voor Geneeskunde van België 62 (2000) 245-267
9. Crowcroft N.S., Stein C., Duclos P., and Birmingham M. How best to estimate the global burden of pertussis?. Lancet Infectious Diseases 3 (2003) 413-418
10. Deen F. Verboden te prikken. Volkskrant Magazine June (2004) 23-26
11. DiMaggio P., and Powell W.W. The iron cage revisited: Institutional isomorphism and collective rationality in organizational fields. American Sociological Review 48 (1983) 147-160
12. Elliman D., and Bradford H. Perhaps it is not time to switch from whole cell to acellular pertussis vaccine. British Medical Journal 321 (2000) 451
13. European Commission, DG XII (1998). ACELLUVAX: Social acceptance and economic impact of a recombinant vaccine. Brussels. Document EUR 18311 en.
14. Gangarosa E.J., Galazka A.M., Wolfe C.R., Phillips L.M., Gangarosa R.E., Miller E., et al. Impact of anti-vaccine movements on pertussis control: The untold story. Lancet 351 (1998) 356-361
15. Geier G.D., and Geier M. The true story of pertussis vaccination: A sordid legacy. Journal of the History of Medicine 57 (2002) 249-284
16. Gezondheidsraad. (2004). Vaccinatie tegen kinkhoest. Den Haag, document {music sharp sign} 04.
17. Global Programme for Vaccines and Immunization. WHO position paper on Haemophilus influenza type b conjugate vaccine. Weekly Epidemiological Record 73 (1998) 64-68
18. Girard D.Z. Which strategy for pertussis vaccination today?. Paediatric Drugs 4 (2002) 299-313
19. Grabowski H.G., and Vernon J.M. The search for new vaccines: The effects of the vaccines for children program (1997), AEI Press, Washington, DC
20. Granström M. The history of pertussis vacination: From whole-cell to subunit vaccines. In: Plotkin S.A., and Fantini B. (Eds). Vaccinia vaccination and vaccinology (1996), Elsevier, Paris 107-114
21. Hardon A., and Blume S. Shifts in global immunisation goals (1984-2004): Unfinished agendas and mixed results. Social Science and Medicine 60 (2005) 345-356
22. Het Parool (2004). 5 January.
23. Iskedjian M., Einarson T.R., O'Brien B.J., De Serres J.G., Gold R., Gemmill I.M., et al. Economic evaluation of a new acellular vaccine for pertussis in Canada. Pharmacoeconomics 19 (2001) 551-563
24. Lindner U. Gesundheitspolitik in der Nachkriegszeit (2004), Grossbritannnien und die Bundesrepublik Deutschland im Vergeleich München, Oldenbourg Verlag
25. Madhavi Y. Manufacture of consent? Hepatitis B vaccination. Economic and Political Weekly June (2003) 2417-2424
26. Melker H.E., Schellekens J.F.P., Neppelenbroek S.E., and Conyn-van Spaendonck M.A.E. Epidemiologie van kinkhoest in Nederland: Observaties op grond van surveillancegegevens. Nederlands Tijdschrift Medical Microbiologie 4 (2000) 101-106
27. Miller E. Overview of recent clinical trials of acellular pertussis vaccines. Biologicals 27 (1999) 79-86
28. Milstien, J., Candries, B. (2002). Economics of vaccine development and implementation: changes over the past 20 years. www.who.int/vaccines-access/supply; Accessed January 2005.
29. In: Mitchell V.S., Philipose N.M., and Stanford J.P. (Eds). The children's vaccine initiative: Achieving the vision (1993), National Academy Press, Washington, DC
30. Mooi F.R., van Oirschot H., Heuvelmans K., van der Heide H.G., Gaastra W., and Willems R.J. Polymorphism in the B pertussis virulence factors P69/pertactin and pertussis toxin in the Netherlands: Temporal trends and evidence for vaccine-driven evolution. Infection Immunity 66 (1998) 670-675
31. Mowery D.C., and Mitchell V. Improving the reliability of the US vaccine supply: An evaluation of alternatives. Journal of Health Policy Politics and Law 20 (1995) 973-1000
32. Muraskin W. The global alliance for vaccines and immunization: Is it a new model for effective public-private cooperation in international public health?. American Journal of Public Health 94 (2004) 1922-1925
33. National Advisory Committee on Immunization (1997). Statement on pertussis vaccine. Canada Communicable Disease Report; 23(ACS-3).
34. Office of Technology Assessment. A review of selected federal vaccine and immunization policies (1979), US Government Printing Office, Washington, DC
35. Olin P., Rasmussen F., Gustafsson L., Hallander H., and Heijbel O. Randomised controlled trial of two-component, three component and five component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Lancet 350 (1997) 1569-1577
36. Plotkin S.A., and Cadoz M. The acellular pertussis vaccine trials: an interpretation. Pediatric Infectious Disease Journal 16 (1997) 508-517
37. Sato Y., Kiruma M., and Fukumi H. Development of a pertussis component vaccine in Japan. Lancet 1 (1984) 122-126
38. Stanton J. What shapes vaccine policy: The case of hepatitis B in the UK. Social History of Medicine 7 (1994) 427-446
39. Stewart G.T. Vaccination against whooping cough. Efficacy versus risks. Lancet 8005 (1977) 234-237
40. Ström J. Is universal vaccination against pertussis always justified?. British Medical Journal 1184 (1960) 12
41. Wenger J.D., DiFabio J.-L., Landaverde J.M., Levine O.S., and Gaafar T. Introduction of Hib conjugate vaccines in the non-industrialized world: Experience in four 'newly adopting' countries. Vaccine 18 (2000) 736-742
42. Woodle D. Vaccine procurement and self-sufficiency in developing countries. Health Policy and Planning 15 (2000) 121-129
43. World Health Organisation, Department of Vaccines and Biologicals. Report of a meeting of international public sector vaccinology institutions (2000), WHO, Geneva (March 2000)